BioWorld MedTech

Jan. 29, 2016

Engaged Under Pressure: Heartware nixes Valtech deal citing 'different set of circumstances'

Just three weeks after vehemently defending its proposed acquisition of Valtech Cardio Ltd. (Yehuda, Israel), Heartware International Inc. (Framingham, Mass.) nixed the stock-based deal, which was valued at $929 million and announced in September. Read More

Inside the Beltway: CMS advises Theranos Medicare privileges at risk after inspection

Beat Target in Down Market: Vexim raises $11 million to challenge spine market in the US

Path to care paved with good intentions: Boston Sci, Accenture develop Advantics Care Pathway solution for HF patients

Financings: Neurotrack raises $6.5 million

Court Report: Oral argument calendared for Retractable Technologies, BD case

Product briefs

People in Places

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for July 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 23, 2025.

Illustration of group of people with chromosomes floating above

A fresh look at 1000 Genomes is more detailed, and more panoramic

BioWorld

The human genome has yielded another round of secrets with the publication of two back-to-back papers in Nature on July 23, 2025. Both studies re-sequenced...

Newco sends up Flare in bid to Dispatch solid tumors

BioWorld

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture...

GABRA5 modulation supports treatment of neurodevelopmental disorders

BioWorld Science

Alterations in the GABAergic pathway in the brain contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder and...